Pattern of Failure after Helical Tomotherapy in Head and Neck Cancer

Farrag, Ashraf; Voordeckers, Mia; Tournel, Koen; Coninck, P. De; Storme, Guy

doi:10.1007/s00066-010-2130-5

Cited by 40 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 Volumetricmodulated arc therapy, a form of rotational IMRT, and stereotactic RT, a form of highly focused irradiation using tridimensional tumor targeting, also offer advantages. 13 Arc therapy reduces IMRT delivery time from 20 minutes to fewer than 5 minutes, while optimizing dose homogeneity and normal tissue sparing, [14][15][16][17][18][19][20][21][22][23][24][25] including parotid gland sparing. 26 Stereotactic fractionated RT allows for the generation of x-ray beams from a single electronic source, which can be rotated or moved around a central focus.…”

Section: Chemoradiation Therapymentioning

confidence: 99%

Oral complications of cancer and cancer therapy

Epstein

Thariat

Bensadoun

et al. 2012

CA A Cancer J Clinicians

412

356

View full text Add to dashboard Cite

Answer questions and earn CME/CNEOral complications resulting from cancer and cancer therapies cause acute and late toxicities that may be underreported, underrecognized, and undertreated. Recent advances in cancer treatment have led to changes in the incidence, nature, and severity of oral complications. As the number of survivors increases, it is becoming increasingly recognized that the aggressive management of oral toxicities is needed to ensure optimal long‐term oral health and general well‐being. Advances in care have had an impact on previously recognized oral complications and are leading to newly recognized adverse effects. Here, the authors briefly review advances in cancer therapy, including recent advances in surgery, oral care, radiation therapy, hematopoietic cell transplantation, and medical oncology; describe how these advances affect oral health; and discuss the frequent and/or severe oral health complications associated with cancer and cancer treatment and their effect upon long‐term health. Although some of the acute oral toxicities of cancer therapies may be reduced, they remain essentially unavoidable. The significant impact of long‐term complications requires increased awareness and recognition to promote prevention and appropriate intervention. It is therefore important for the primary oncologist to be aware of these complications so that appropriate measures can be implemented in a timely manner. Prevention and management is best provided via multidisciplinary health care teams, which must be integrated and communicate effectively in order to provide the best patient care in a coordinated manner at the appropriate time. CA Cancer J Clin 2012. © 2012 American Cancer Society.

show abstract

Section: Chemoradiation Therapymentioning

confidence: 99%

Oral complications of cancer and cancer therapy

Epstein

Thariat

Bensadoun

et al. 2012

CA A Cancer J Clinicians

412

356

View full text Add to dashboard Cite

show abstract

“…One approach has been to determine the site of recurrence origin directly on the treatment planning scan [9]. Other studies have transferred the delineated recurrence volume by coregistration or expert opinion to the treatment planning scan and ascribed the recurrence to the highest isodose level encompassing either 50% or 95% of the recurrence volume [6,13,17,18,19]. The volume overlap method has some inherent weaknesses, especially when the purpose is to analyze the relation of the recurrence to small regions, and we recently published a pilot study introducing the concept of a focal method in order to analyze the pattern of failure with a spatial resolution matching the achievable dose modulation in dose-painted radiotherapy [5].…”

mentioning

confidence: 99%

Methods for estimating the site of origin of locoregional recurrence in head and neck squamous cell carcinoma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…It is important to note that the reports used were published between 1966 and 1996 where three-dimensional (3D) planning was not yet standard. It is doubtful whether these data are applicable for currently used modern radiotherapy techniques such as intensity modulated radiotherapy (IMRT) [14,19]. A recent review reasoned that it is not possible to draw firm conclusions as data are limited due to the small number of patients developing myelopathy [22].…”

mentioning

confidence: 99%